Different pathways have been reported to be involved in platelet -collagen interaction. We have reported that the platelet endothelial form of nitric oxide synthase (eNOS) and the platelet receptor for type I collagen, p65, are closely associated. But the controlling mechanism underlying the generation of nitric oxide (NO) by the eNOS has not been fully explored. In this investigation, Western blot analyses of time course samples with anti-phosphorylated tyrosine, and anti-serine/threonine showed a marked increase in serine/threonine phosphorylation of eNOS during type I collagen-induced platelet aggregation. Meanwhile, the eNOS activity measured by the conversion of [ 3 H]-arginine to [ 3 H]-citrulline is significantly decreased. Correlation of type I collagen-induced platelet aggregation and the activity of eNOS in the presence of the serine/threonine phosphatase inhibitor, okadiac acid and the tyrosine phosphatase inhibitor, vanadate were performed with PRP. Results show the decrease in eNOS activity by adding okadiac acid correlated with the inhibitory effect on platelet aggregation in a dosedependent manner. On the other hand, vanadate significantly inhibits platelet aggregation and also inhibits eNOS activity when the concentration of vanadate is greater than 2 mM. These results suggest that phosphorylation of serine/threonine and tyrosine residues control the activity of eNOS through different mechanisms to affect collagen-induced platelet aggregation. D
Introduction
Platelets play an important role in the process of homeostasis and thrombosis. Following injury to blood vessels and in certain pathologic conditions, platelets adhere to the exposed subendothelial connective tissue (collagen in particular), aggregate, and release several biologically active substances. The adherence of platelets to the subendothelial component collagen has been demonstrated to be a receptormediated event [1 -3] .
Collagen-platelet interaction involves two groups of platelet proteins: integrin a2h1 [4] and non-integrin receptors including p65, glycoprotein VI, and glycoprotein IV (for review see Refs. [5, 6] ). Many reports have shown that signal transduction pathways seem different between integrin and glycoprotein VI [7 -9] . The signal transduction pathway for other non-integrin receptors are not known. We have reported that p65 is associated with endothelial nitric oxide synthase (eNOS) [10] . Furthermore, we reported that nitrosylated recombinant 65 kDa proteins fail to inhibit type I collagen-induced platelet aggregation [11] . The controlling mechanism, however, of eNOS is not established.
Nitric oxide (NO) produced by various cells (especially the endothelial cells) was noted to be important in inhibiting adhesion and aggregation of platelets. Recently, the platelets themselves have been shown to synthesize NO [12 -15] . This supposedly serves to inhibit the recruitment of other platelets, thereby keeping aggregation under control [16, 17] . It is also known that the activity of NO synthase decreases once platelet aggregation has occurred. In an in vitro model study, NO has been reported to reduce thrombus growth [18] . The generation of NO by the platelet could lead to regulatory effects within the platelet itself as well as on elements in the surrounding environment. NO can modulate certain hemoprotein enzymes in the biosynthetic cascade that governs the formation of eicosanoid mediators of thrombosis and hemostasis, including prostaglandin I2 synthase and thromboxane A2 synthase [19] .
In the present investigation, we have found that there is a close association between the activity of eNOS and the p65 platelet non-integrin receptor. The activity of eNOS is controlled by serine/threonine and tyrosine phosphorylation.
Materials and methods

Materials
Materials used in this investigation included anti-eNOS (Transduction Lab., Lexington, KY), anti-phosphotyrosine and anti-phosphoserine/phosphothreonine (Upstate Biotechnology, Lake Placid, NY). Type I collagen solution was purchased from Chrono-Log Corp. (Havertown, PA). All other chemicals were from Sigma Chemical Co. (St. Louis, MO), Fisher Scientific (St. Louis, MO), Bio-Rad Lab. (Hercules, CA), and Pierce (Rockford, IL).
Preparation of platelet-rich plasma (PRP)
Human blood (nine parts) from healthy volunteers was collected in polypropylene tubes containing one part 3.8% sodium citrate after an overnight fast. PRP was prepared by centrifuging the citrated blood at room temperature for 10 min at 226 Â g [20] . Whole blood and PRP were exposed to plastic surfaces or siliconized vessels only. Platelet counts of the PRP (ranging from 200,000 to 300,000 per mm 3 ) were determined by phase contrast microscopy (using a hemocytometer).
Preparation of type I collagen
Collagen was prepared from human placenta according to Seyer et al. [21] . The concentration of the collagen solutions was determined by amino acid analysis after hydrolysis with 6 N HCl [22] .
Platelet aggregometry
Platelet aggregation was measured by the turbidimetric method of Born [23] using a Lumiaggregometer (ChronoLog). (22 jC) . The reaction was stopped with 2 ml 20 mM Hepes, pH 5.5/2 mM EDTA and the mixture applied to 1 ml columns of Dowex AG50WX-8 (Na + form), which were eluted with 2 ml of water. [ 3 H]-citrulline was quantified by a liquid scintillation spectrometer (Packard Instrument) with 15 ml ScintiVerse BD (Fisher Scientific). A boiled lysate was used as a background control. Activity was determined by the recovery of the end product, labeled citrulline, which is produced in molar equivalence to NO in the supernatant. Activity was expressed as the mean of picomoles of citrulline formed/number of platelets from duplicate experiments.
Assay of the activity of NOS
Western blot
Platelets were harvested by centrifugation after exposure to type I collagen. Platelet pellets were resuspended in 20 mM Tris -HCl buffer (pH 7.4) containing enzyme inhibitors (25 AM aprotinin, 25 AM leupeptin, and 1 AM PMSF). The suspension was sonicated for 20 s at 4 jC and an aliquot of SDS-PAGE sample buffer was added. The suspension was then boiled for 3 min and analyzed by 10% SDS-PAGE [26] . Protein bands were electrophoretically transferred onto nitrocellulose membrane, followed by treatment with 3% dried milk in TBS (20 mM Tris -500 mM NaCl -0.05% Tween 20, pH 7.4) to eliminate non-specific binding. The nitrocellulose sheet was then washed three times with TBS and incubated with its respective antibody overnight at 4 jC. After washing three times in TBS, the nitrocellulose sheet was incubated with a second antibody (peroxidase conjugated goat anti-mouse IgG, 1/20,000) for 2 h at room temperature. After three washings with TBS, the nitrocellu- Fig. 1 . Comparison of basal levels of treatments. We have performed treatments to establish a baseline for the subsequent experiments. We have three treatments as follows: lane 1, PRP without adding collagen; lane 2, PRP with PBS but no collagen added; and lane 3, PRP with collagen at zero time. Platelets were harvested from these treatments, washed with 0.5 ml PBS, suspended in SDS-PAGE sample buffer, and sonicated for 10 s. These samples were boiled for 3 min, and analyzed by 7.5% SDS-PAGE. After transferring onto a nitrocellulose sheet, Western blots were analyzed with three antibodies (1/1000) as indicated in the figure. The dilution of the second antibody (peroxidase conjugated anti-goat IgG) was 1/20,000 and development was with ECL solutions. Changes in band intensities are under each band and were determined by the Bio-Rad computer programQuality One. The data shown are from one experiment which is representative of two others that gave similar results.
lose sheet was developed with ECL solution as described by the manufacturer (Amersham, Arlington Heights, IL) [11] .
Results
It is well established that NO is involved in collagenplatelet interaction. But the exact mechanism whereby NO acts is not firmly established. We have previously reported that eNOS and p65 co-precipitate using either anti-eNOS or anti-p65 [11] . We tried to examine whether the association of these two components could contribute to eNOS activity during type I collagen-induced platelet aggregation. A time course correlation between these components during type I collagen-induced platelet aggregation was made with Western blot analyses through the use of various antibodies obtained from commercial sources.
We have performed experiments to establish the baseline in different conditions such as PRP without adding collagen, PRP with PBS but no collagen added, and PRP with collagen at zero time. Results showed that there are no differences in all of these conditions (Fig. 1) . We have also assayed the NOS activity. The results expressed as mean F S.D. of these three conditions (PRP control without adding collagen-NOS activity is 2.42 F 02, PRP with PBS but no collagen added-NOS activity is 2.43 F 0.15, and PRP with collagen at zero time-NOS activity is 2.39 F 0.15) are quite similar. For the purpose of correlating the time course of platelet aggregation and changing of An aliquot of 0.45 ml PRP was incubated with the above listed agents for 10 min. At the end of the pre-incubation, collagen (0.5 Ag) was added to each tube and incubated for 2 min. The mixture was centrifuged and washed with PBS. An aliquot of assay buffer (50 Al) was added to each tube and sonicated for 10 s. Other assay components were added to each tube and the reaction was initiated with [ 3 H]-arginine. The reaction was incubated for 5 min at 22 jC and stopped with 2 ml stopping buffer. [ 3 H]-citrulline was recovered from the reaction mixture by Dowex column. Radioactivity was assessed by a scintillation counter. Data are expressed as mean F S.D. of experiment in triplicates. Numbers in brackets are calculated as percentages of PBS. Platelet aggregation was determined with a Chrono-Log aggregometer in triplicates. Platelet aggregation (PA %) was recorded at 2 min after addition of collagen. The data shown are from one experiment representative of two others that gave similar results. OA, okadiac acid; V, vanadate; and C, collagen. various parameters, we performed a time course experiment of type I collagen-induced platelet aggregation (Fig. 2,  curve b) . As can be seen, type I collagen-induced platelet aggregation is time-dependent. After the addition of collagen, platelets undergo shape change and then aggregate. The response of platelets to the vehicle control (PBS) is shown in Fig. 2, curve a. It has been reported that phosphorylation affects the activity of eNOS [27 -30] . We have used the course of change in phosphorylation of eNOS as the time frame to guide our sampling during type I collagen-induced platelet aggregation. Fig. 3 shows the Western blots of anti-eNOS, anti-phosphoserine/threonine, and anti-phosphotyrosine samples at different time intervals. As can be seen in the left panel of Fig. 3 , the amount of eNOS protein decreases about 20% during type I collagen-induced platelet aggregation. There is a time-dependent increase (two-to three-fold) in serine/threonine phosphorylation of eNOS during type I collagen-induced platelet aggregation (middle panel). The phosphorylation of serine/threonine moieties of eNOS reaches its maximum at 1 min during which time platelets undergo shape change. There is also a time-dependent increase (two-fold) in tyrosine phosphorylation of eNOS (right panel). The increase in phosphotyrosine of eNOS reaches its maximum at 30 s, which is before platelet shape changes. These results suggest that type I collagen induces platelet aggregation and decreases NO production which may be mediated by the serine/threonine or tyrosine phosphorylation of eNOS.
An attempt was made to correlate the eNOS activity and type I collagen -platelet aggregation by serine/threonine and tyrosine phosphatase inhibitors. Okadiac acid is a serine/ threonine phosphatase inhibitor and vanadate is a tyrosine phosphatase inhibitor (Table 1) . As shown in the table, there is a correlation between type I collagen-induced platelet aggregation and the activity of eNOS. Both were inhibited by okadiac acid in a dose-dependent manner. On the other hand, there is no correlation of inhibitory effect of vanadate on the activity of NOS and type I collagen-induced platelet aggregation. The combination of low concentrations of both inhibitors seems to inhibit both the activity of eNOS and type I collagen-induced platelet aggregation.
To ensure that the serine/threonine and tyrosine phosphorylation of eNOS can regulate the activity of eNOS, we assayed the activity of eNOS by the conversion to [ 3 H]-citrulline of [ 3 H]-arginine. As shown in Fig. 4 , the activity of eNOS decreased over the time frame of type I collageninduced platelet aggregation compared to control samples.
Discussion
In the present investigation, we have studied the relationship among the activity of eNOS, phosphorylation of serine/ threonine and tyrosine of eNOS, and type I collageninduced platelet aggregation. The results of this study demonstrate that there is a marked increase in the platelet eNOS phosphorylation on serine/threonine that correlates with the inhibition of platelet aggregation. On the other hand, tyrosine phosphorylation of eNOS slightly changes eNOS activity. These results were confirmed by using inhibitors such as okadiac acid and vanadate for serine/ threonine and tyrosine phosphoprotein phosphatases.
We have previously reported that p65 and eNOS coprecipitate but the time course of the interaction had not been examined and the nitrotyrosylation of eNOS could not be demonstrated. The results suggested that nitrotyrosylation was not a control point for the NO produced during type I collagen-induced platelet aggregation [11] . In order to define a mechanism of control for the NO generated, we tested several possible factors to see whether any of these might affect eNOS enzyme activity. As we report here, the activity of eNOS decreases with time during type I collagen-induced platelet aggregation while the intensity of the phosphorylation of serine/threonine showed marked increases with a slight increase in the tyrosine moieties of the eNOS. These results support the current paradigm that the activity of eNOS is controlled by serine/threonine phosphorylation and perhaps by tyrosine phosphorylation [30 -32] .
Many laboratories have shown that serine/threonine phosphorylation of eNOS at different sites controls eNOS activity [31 -33] . Michell et al. [34] have reported that eNOS is primarily phosphorylated on serine and to a lesser extent on tyrosine and threonine residues. The presence of the phosphoprotein phosphatase 1 and other species of phosphoprotein phosphatases in platelets may play a role in controlling phosphorylation of serine/threonine of the eNOS. We have reported that the phosphoprotein phosphatase 1 inhibitor, okadiac acid, inhibits dephosphorylation of serine/threonine residues, inhibits type I collagen-induced platelet aggregation, and the release of ATP [35, 36] . In the present investigation, we observed that okadiac acid inhibits eNOS activity which correlates with the inhibition of platelet aggregation in a dose-dependent manner. This result is consistent with our earlier finding that okadiac acid, a serine/threonine protein phosphatase inhibitor, inhibits type I collagen-induced platelet aggregation [35] . On the other hand, vanadate, a tyrosine phosphatase inhibitor has an inhibitory effect on type I collagen-induced platelet aggregation and also inhibits eNOS activity. This result suggests that the phosphotyrosine phosphatase inhibitor, vanadate, inhibits type I collagen-induced platelet aggregation and is different from the phosphoserine/threonine phosphatase inhibitor, okadiac acid.
Endothelial NOS phosphorylation on serine residues by protein kinase C (PKC) and cAMP-dependent protein kinase (PKA) has been reported [28, 36] . The phosphorylation of serine/threonine residues on platelet eNOS is probably controlled by PKC but not by PKA because collageninduced platelet aggregation decreases cAMP content but activates PKC [37 -39] . However, serine phosphorylation of eNOS is essential for the cellular regulation of eNOS function. It might either increase or decrease its activity, depending on the kinase and the location of the serine residue involved.
In summary, the activity of eNOS decreases during type I collagen-induced platelet aggregation and may be controlled by different mechanisms involving associations with differential phosphorylation of specific amino acid residues located in the eNOS.
